HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 12, Pages 3734
Publisher
MDPI AG
Online
2020-12-14
DOI
10.3390/cancers12123734
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The disordered N-terminus of HDAC6 is a microtubule-binding domain critical for efficient tubulin deacetylation
- (2020) Kseniya Ustinova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
- (2020) Sara Moufarrij et al. Scientific Reports
- Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2020) Ka Yang et al. ACS Medicinal Chemistry Letters
- Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
- (2020) Sanghoon Lee et al. Cell Reports
- Developing potent PROTACs tools for selective degradation of HDAC6 protein
- (2019) Zixuan An et al. Protein & Cell
- Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models
- (2019) Yves Depetter et al. INTERNATIONAL JOURNAL OF CANCER
- High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma
- (2019) Jia-Rong Liu et al. BIOCHEMICAL PHARMACOLOGY
- Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer
- (2019) Caroline Kreuzinger et al. CANCER LETTERS
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Ovarian cancer: Current status and strategies for improving therapeutic outcomes
- (2019) Ashwin Chandra et al. Cancer Medicine
- Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway
- (2019) Philipp Ottis et al. ACS Chemical Biology
- Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy
- (2019) Keiichi Fujiwara et al. CANCER
- Biomarkers in ovarian cancer: To be or not to be
- (2019) Rebecca Arend et al. CANCER
- ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
- (2018) Joseph J. Caumanns et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6
- (2018) G. R. Vanaja et al. Cell Communication and Signaling
- Association of histone deacetylase expression with histology and prognosis of ovarian cancer
- (2018) Mitsutake Yano et al. Oncology Letters
- Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways
- (2018) Jinlin Cao et al. Cell Death & Disease
- The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study
- (2017) Roberta Sferra et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ARID1A-mutated ovarian cancers depend on HDAC6 activity
- (2017) Benjamin G. Bitler et al. NATURE CELL BIOLOGY
- The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease
- (2016) S. N. Batchu et al. CLINICAL SCIENCE
- SIRT2 inactivation reveals a subset of hyperacetylated perinuclear microtubules inaccessible to HDAC6
- (2016) Renate Hvidsten Skoge et al. JOURNAL OF CELL SCIENCE
- Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
- (2016) Pengyu Huang et al. Oncotarget
- Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer
- (2015) Younghee Park et al. Journal of Breast Cancer
- Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells
- (2015) Karolina Weiner-Gorzel et al. Cancer Medicine
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement
- (2013) Virginia A. Moyer ANNALS OF INTERNAL MEDICINE
- HDAC6 siRNA Inhibits Proliferation and Induces Apoptosis of HeLa Cells and its Related Molecular Mechanism
- (2013) Hai-Xia Qin et al. Asian Pacific Journal of Cancer Prevention
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis
- (2013) Raul Aguirre-Gamboa et al. PLoS One
- Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
- (2013) Michael S. Anglesio et al. PLoS One
- The Changing View of High-Grade Serous Ovarian Cancer
- (2012) E. M. J. J. Berns et al. CANCER RESEARCH
- Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance
- (2012) David J. Pinato et al. CANCER TREATMENT REVIEWS
- Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ
- (2012) Huilian Hou et al. JOURNAL OF CLINICAL PATHOLOGY
- NY-BR-1 and PAX8 Immunoreactivity in Breast, Gynecologic Tract, and Other CK7+ Carcinomas
- (2011) Anna H. Woodard et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer
- (2011) Fiona Furlong et al. JOURNAL OF PATHOLOGY
- Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines
- (2010) Adriano Angelucci et al. GYNECOLOGIC ONCOLOGY
- Calculator for ovarian carcinoma subtype prediction
- (2010) Steve E Kalloger et al. MODERN PATHOLOGY
- Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas
- (2009) Lena Marquard et al. HISTOPATHOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of Pax8 as a Useful Marker in Distinguishing Ovarian Carcinomas From Mammary Carcinomas
- (2008) Daisuke Nonaka et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
- Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
- (2008) M. Bazzaro et al. CLINICAL CANCER RESEARCH
- Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
- (2008) Y. Zhang et al. MOLECULAR AND CELLULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now